Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Evaluation of patient care interventions and recommendations by a transitional care pharmacist

Authors K Bruce Bayley, Lucy A Savitz, Teresa Maddalone, Stephen E Stoner, Jacquelyn S Hunt, Robert Wells

Published 15 September 2007 Volume 2007:3(4) Pages 695—703

K Bruce Bayley1, Lucy A Savitz2, Teresa Maddalone3, Stephen E Stoner4, Jacquelyn S Hunt5, Robert Wells6

1Center for Outcomes Research and Education, Providence Health and Services, Portland, Oregon, USA; 2Abt Associates, Durham, North Carolina, USA; 3Providence Physician Division, Providence Health and Services, Portland, Oregon, USA; 4Regional Clinical Pharmacy Services, Providence Health and Services, Portland, Oregon, USA; 5Providence Physician Group, Providence Health and Services, Portland, Oregon, USA; 6Providence Portland Medical Center, Providence Health and Services, Portland, Oregon, USA

Abstract: A “transitional care pharmacist” (TCP) was deployed within an acute care setting to identify opportunities for improved continuity of care. The provision of medication reconciliation services, drug consultation, patient counseling and planning for after-hospital care was time consuming but also fruitful, resulting in roughly nine interventions per patient. Areas with the greatest potential for morbidity reduction were the resumption of home medications during the acute stay and at discharge. Allergy identification was a key contribution at admission, as was the provision of a detailed follow-up plan at discharge. Targeting high-risk patients and spreading portions of the work to other disciplines could achieve added efficiency in this service. Results have value to hospitals implementing medication reconciliation programs.

Keywords: patient safety, medication reconciliation, transitional care, pharmacist

Download Article [PDF] 

Readers of this article also read:

In vitro cytotoxicity of the ternary PAMAM G3–pyridoxal–biotin bioconjugate

Uram Ł, Szuster M, Gargasz K, Filipowicz A, Wałajtys-Rode E, Wołowiec S

International Journal of Nanomedicine 2013, 8:4707-4720

Published Date: 11 December 2013

Vaccination against hepatitis A in children: A review of the evidence

Paolo Bonanni, Sara Boccalini, Angela Bechini

Therapeutics and Clinical Risk Management 2007, 3:1071-1076

Published Date: 15 January 2008

Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors

Jean-Pierre Armand, Vincent Ribrag, Jean-Luc Harrousseau, Lauren Abrey

Therapeutics and Clinical Risk Management 2007, 3:213-224

Published Date: 15 May 2007

Bortezomib (Velcade™) in the treatment of multiple myeloma

Antonia Field-Smith, Gareth J Morgan, Faith E Davies

Therapeutics and Clinical Risk Management 2006, 2:271-279

Published Date: 15 September 2006